Ardelyx Gelecekteki Büyüme
Future kriter kontrolleri 6/6
Ardelyx kazanç ve gelirin sırasıyla yıllık 56.5% ve 24.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 56.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 55.2% olacağı tahmin edilmektedir.
Anahtar bilgiler
56.5%
Kazanç büyüme oranı
56.37%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 23.4% |
| Gelir büyüme oranı | 24.1% |
| Gelecekteki özkaynak getirisi | 55.21% |
| Analist kapsamı | Good |
| Son güncelleme | 01 May 2026 |
Gelecekteki son büyüme güncellemeleri
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its Third-Quarter Report
Nov 02
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Recent updates
ARDX: Extended 2042 Patent Horizon Will Support Multiyear Revenue Roadmap
The analyst fair value estimate for Ardelyx has increased from $10.00 to $13.00, supported by recent price target revisions and analyst views that the new patent extending to November 2042 strengthens the company’s long-term profile. Analyst Commentary Recent research commentary around Ardelyx centers on the updated patent timeline to November 2042 and how that may influence valuation assumptions.
ARDX: Extended Patent Runway And 2029 Revenue Guidance Will Support Repricing
Ardelyx's consensus analyst price target has moved higher toward $19, with the shift largely tied to stronger Ibsrela revenue guidance, extended patent protection into the 2040s, and analyst expectations reflected in updated P/E, growth, and margin assumptions. Analyst Commentary Bullish analysts have been revising their views higher, with a series of price target increases and rating upgrades clustering around Ardelyx's updated Ibsrela guidance and extended patent protection.
ARDX: Extended Patent Life And IBS Guidance Are Expected To Unlock Upside
The analyst fair value estimate for Ardelyx has been raised from $13.50 to $16.10. Analysts point to higher Ibsrela revenue guidance, extended intellectual property protection into the 2040s, and a series of upward revisions to Street price targets as key drivers of the change.ARDX: Extended Patent Runway And 2029 Revenue Outlook Will Drive Bullish Repricing
Ardelyx's analyst price target has moved higher, with several firms lifting their views into a $14 to $19 range. Analysts highlight extended patent protection on key assets, updated Ibsrela revenue guidance that includes targets of $410m to $430m in FY26 and $1b by 2029, and a stronger outlook for the broader product portfolio and cash position.ARDX: Extended Patent Runway And 2029 Revenue Path Will Support Bullish Outlook
The analyst fair value estimate for Ardelyx has shifted from $16.00 to $19.00, as analysts factor in higher projected revenue, updated profitability assumptions, and extended intellectual property protection highlighted in recent research notes. Analyst Commentary Recent Street research on Ardelyx has leaned firmly positive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings after management updates and new patent developments.Ardelyx: Strong IBSRELA Growth, But Heavy Operational Spend Clouds Profitability
Feb 20ARDX: Multiyear Revenue Roadmap And CIC Expansion Will Drive Upside
Analysts lifted their fair value estimate for Ardelyx to $10.00 from $8.00, citing updated Street research that highlights stronger Ibsrela revenue guidance toward $410m to $430m by FY26 and a US$1b annual revenue outlook by 2029, along with pipeline progress and a solid cash position. Analyst Commentary Recent Street research has centered on Ibsrela guidance of US$410m to US$430m in FY26 and the long term US$1b annual revenue outlook for 2029, with several firms adjusting price targets and ratings to reflect those inputs, as well as updates on Xphozah, the broader pipeline, and the cash position.ARDX: Faster Path To 1b Revenue Is Expected To Unlock Upside
We are raising our Ardelyx fair value estimate from $12.30 to $13.50 as analysts point to higher Ibsrela revenue expectations, a faster ramp to the company’s $1b annual revenue goal, and updated guidance that supports stronger margins and a lower forward P/E multiple. Analyst Commentary Recent Street research is broadly constructive on Ardelyx, with multiple firms lifting price targets after the latest Ibsrela revenue outlook and guidance update.Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Jan 21ARDX: Higher Revenue Guidance Is Expected To Support Long Term Upside
Narrative Update on Ardelyx The analyst price target for Ardelyx has shifted higher, with our fair value estimate moving from US$11.60 to US$12.30 as analysts factor in stronger Ibsrela revenue guidance and updated Street targets of up to US$19. Analyst Commentary Recent Street research on Ardelyx has focused heavily on updated Ibsrela revenue guidance and how that might influence the company’s valuation and execution priorities over the next several years.ARDX: Long-Term Profitability Improvements Will Drive Stronger Bullish Outlook
Analysts have raised their price target on Ardelyx from 15 dollars to 16 dollars. This reflects slightly stronger expectations for long term revenue growth, improved profitability, and a modestly lower future earnings multiple despite a higher discount rate.ARDX: Upcoming Leadership Transition Will Support Long Term Earnings Upside
Analysts have modestly reiterated their confidence in Ardelyx, keeping the price target essentially unchanged at approximately 11.60 dollars per share. Minor adjustments to the discount rate and valuation inputs did not materially alter their long term earnings and growth outlook for the company.ARDX: Commercial Execution Will Drive Shares Higher Under New Leadership
Ardelyx’s analyst price target has been raised from $12 to $14, a $2 increase. Analysts cite stronger commercial execution and discounted valuation under new management as key drivers for the higher outlook.ARDX: Ongoing Commercial Execution Will Unlock Upside From Discounted Levels
Analysts have raised Ardelyx’s fair value estimate from $11.36 to $11.73, citing stronger commercial execution, increased revenue growth potential, and a more favorable profit margin outlook. Analyst Commentary Recent coverage initiations have highlighted key perspectives among market observers evaluating Ardelyx’s trajectory and valuation.Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its Third-Quarter Report
Nov 02Ardelyx, Inc. (NASDAQ:ARDX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Oct 11There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise
Jul 11Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet
May 15
Omnichannel Investments And Sales Teams Will Create Future IBSRELA Demand
Strategic investments and an expanded sales team are expected to drive demand for IBSRELA, boosting revenue and market share.Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Feb 24There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues
Feb 17Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
Dec 20Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Nov 24Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Nov 14Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 03Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
Oct 24Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Aug 25Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Aug 07Ardelyx Faces Rising Challenges Despite Revenue Growth
Aug 05Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 04Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Jul 13Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
Jul 05Ardelyx: Strong Execution, Fairly Valued
May 10Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 04Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
May 03Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
Apr 17Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Mar 13Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 24Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Feb 20Ardelyx's XPHOZAH Still An Afterthought To The Pros
Jan 31Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Jan 10Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price
Jan 04Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt
Dec 14Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 984 | 247 | 282 | N/A | 7 |
| 12/31/2027 | 738 | 99 | 161 | 193 | 10 |
| 12/31/2026 | 546 | -8 | -35 | 50 | 10 |
| 3/31/2026 | 428 | -58 | -37 | -36 | N/A |
| 12/31/2025 | 407 | -62 | -44 | -42 | N/A |
| 9/30/2025 | 398 | -57 | -55 | -54 | N/A |
| 6/30/2025 | 386 | -56 | -55 | -53 | N/A |
| 3/31/2025 | 362 | -54 | -49 | -48 | N/A |
| 12/31/2024 | 334 | -39 | -46 | -45 | N/A |
| 9/30/2024 | 252 | -73 | -64 | -63 | N/A |
| 6/30/2024 | 210 | -65 | -86 | -85 | N/A |
| 3/31/2024 | 159 | -66 | -81 | -81 | N/A |
| 12/31/2023 | 124 | -66 | -90 | -90 | N/A |
| 9/30/2023 | 134 | -27 | -67 | -67 | N/A |
| 6/30/2023 | 83 | -56 | -71 | -71 | N/A |
| 3/31/2023 | 63 | -66 | -87 | -87 | N/A |
| 12/31/2022 | 52 | -67 | -70 | -70 | N/A |
| 9/30/2022 | 9 | -114 | -124 | -124 | N/A |
| 6/30/2022 | 5 | -135 | -133 | -133 | N/A |
| 3/31/2022 | 4 | -153 | -137 | -136 | N/A |
| 12/31/2021 | 10 | -158 | -154 | -153 | N/A |
| 9/30/2021 | 11 | -151 | -133 | -131 | N/A |
| 6/30/2021 | 12 | -125 | -118 | -116 | N/A |
| 3/31/2021 | 13 | -105 | -102 | -101 | N/A |
| 12/31/2020 | 8 | -94 | -82 | -81 | N/A |
| 9/30/2020 | 8 | -85 | -75 | -75 | N/A |
| 6/30/2020 | 8 | -91 | -76 | -76 | N/A |
| 3/31/2020 | 6 | -91 | -85 | -85 | N/A |
| 12/31/2019 | 5 | -95 | N/A | -76 | N/A |
| 9/30/2019 | 3 | -103 | N/A | -84 | N/A |
| 6/30/2019 | 0 | -104 | N/A | -90 | N/A |
| 3/31/2019 | 0 | -100 | N/A | -80 | N/A |
| 12/31/2018 | 3 | -91 | N/A | -70 | N/A |
| 9/30/2018 | 45 | -53 | N/A | -47 | N/A |
| 6/30/2018 | 44 | -50 | N/A | -39 | N/A |
| 3/31/2018 | 44 | -53 | N/A | -45 | N/A |
| 12/31/2017 | 42 | -64 | N/A | -65 | N/A |
| 9/30/2017 | N/A | -106 | N/A | -97 | N/A |
| 6/30/2017 | N/A | -114 | N/A | -102 | N/A |
| 3/31/2017 | N/A | -117 | N/A | -103 | N/A |
| 12/31/2016 | N/A | -112 | N/A | -93 | N/A |
| 9/30/2016 | N/A | -98 | N/A | -87 | N/A |
| 6/30/2016 | N/A | -87 | N/A | -75 | N/A |
| 3/31/2016 | 18 | -50 | N/A | -80 | N/A |
| 12/31/2015 | 24 | -30 | N/A | -72 | N/A |
| 9/30/2015 | 30 | -16 | N/A | -54 | N/A |
| 6/30/2015 | 38 | 2 | N/A | -48 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ARDX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.4% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: ARDX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: ARDX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: ARDX şirketinin gelirinin (yıllık 24.1% ) US pazarından (yıllık 11.1% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ARDX şirketinin gelirinin (yıllık 24.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ARDX 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 55.2 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/03 20:50 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ardelyx, Inc. 18 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |